Earnings summaries and quarterly performance for Caris Life Sciences.
Research analysts who have asked questions during Caris Life Sciences earnings calls.
CB
Colleen Babington
Wolfe Research, LLC
2 questions for CAI
Also covers: CARS, GRAL, NTRA +2 more
Daniel Brennan
TD Cowen
2 questions for CAI
Also covers: A, ADPT, AVTR +25 more
Mark Massaro
BTIG, LLC
2 questions for CAI
Also covers: ADPT, AKYA, BLLN +20 more
Michael Ryskin
Bank of America Merrill Lynch
2 questions for CAI
Also covers: A, ALGN, AVTR +29 more
Patrick Donnelly
Citi
2 questions for CAI
Also covers: A, AVTR, BIO +24 more
SS
Sebastian Sandler
JPMorgan Chase & Co.
2 questions for CAI
Also covers: ADPT, ICLR
Subbu Nambi
Guggenheim Securities
2 questions for CAI
Also covers: ADPT, BOLD, BRKR +21 more
Vijay Kumar
Evercore ISI
2 questions for CAI
Also covers: A, ABT, AVTR +23 more
KM
Kyle Mikson
Canaccord Genuity
1 question for CAI
Also covers: AKYA, BDSX, CSTL +13 more
Recent press releases and 8-K filings for CAI.
Caris Life Sciences Announces Strong Q4 and Full-Year 2025 Results with Positive 2026 Guidance
CAI
Earnings
Guidance Update
Revenue Acceleration/Inflection
- Caris Life Sciences reported strong financial results for Q4 2025, with total GAAP revenue of $293 million, representing 125% growth from $130 million in Q4 2024. Full-year 2025 revenue reached $812 million.
- The company achieved positive GAAP Net Income of $82.0 million and Adjusted EBITDA of $106.1 million in Q4 2025, alongside a GAAP gross margin of 75%.
- Caris generated positive GAAP Net Cash from Operating activities of $44.4 million and Free Cash Flow of $39.7 million in Q4 2025, ending the period with $802.3 million in cash, marketable securities, and restricted cash.
- For full-year 2026, Caris initiated guidance expecting total revenue in the range of $1.00 billion to $1.02 billion, reflecting 23%-26% year-over-year growth.
- Operational achievements include a 20% volume growth in clinical cases, completing 52,700 cases in Q4 2025, and announcing a Genentech Discovery Collaboration with a potential total contract value of $1.1 billion.
2 days ago
Caris Life Sciences Reports Strong Q4 and Full-Year 2025 Results, Provides 2026 Guidance, and Details Pipeline Progress
CAI
Earnings
Guidance Update
Product Launch
- Caris Life Sciences reported strong Q4 2025 total revenues of $293 million, a 125% year-over-year increase, contributing to full-year 2025 total revenue growth of 97%. The company achieved GAAP net income of $82 million, adjusted EBITDA of $106 million, and positive free cash flow of $39.7 million in Q4, ending the year with over $800 million in cash.
- Molecular profiling services were a key driver, with Q4 revenues increasing 199% to $282 million and full-year revenues growing 120% to $766.7 million, driven by a 22% increase in clinical case volumes and a 79% increase in average sales price (ASP). Full-year adjusted EBITDA was $138 million and free cash flow was $67 million.
- The company issued 2026 guidance, projecting total revenue for existing solutions between $1.0 billion and $1.02 billion, representing 23%-26% growth. Despite planned significant investments, including a 20%-25% expansion of its sales force and a projected $60 million in CapEx, Caris expects to maintain positive adjusted EBITDA and free cash flow.
- Caris is on track to launch its Caris Detect whole genome sequencing-based MCED blood test in Q2 2026, following interim Achieve 1 study results showing 63.1% sensitivity for stage 1 and 2 cancers and 99.1% specificity in the screening population.
2 days ago
Caris Life Sciences Reports Strong Q4 and Full-Year 2025 Results, Prepares for Caris Detect Launch
CAI
Earnings
Product Launch
New Projects/Investments
- Caris Life Sciences reported strong Q4 2025 results, with total revenues increasing 125% year-over-year to $293 million, contributing to a 97% full-year revenue growth. The company achieved a GAAP net income of $82 million and adjusted EBITDA of $106 million in Q4 2025, marking its third consecutive quarter of positive adjusted EBITDA and free cash flow.
- For the full year 2025, Caris reported adjusted EBITDA of $138 million and free cash flow of $67 million, ending the year with over $800 million in cash on hand.
- Interim results for Caris Detect, a multi-cancer early detection (MCED) blood test, demonstrated 63.1% sensitivity for stage 1 and 2 combined and 99.1% specificity in the screening population. The company anticipates launching Caris Detect in Q2 2026.
- For 2026, Caris expects to achieve positive adjusted EBITDA, with planned investments including $60 million in CapEx for the Caris Detect launch and increased spending in sales and marketing and R&D.
2 days ago
Caris Life Sciences Reports Record Q4 and Full-Year 2025 Results, Provides 2026 Guidance
CAI
Earnings
Guidance Update
Product Launch
- Caris Life Sciences reported a strong Q4 2025 with total revenues increasing 125% year-over-year to $293 million, primarily driven by a 199% increase in molecular profiling services revenue to $282 million.
- For the full year 2025, total revenue grew 97%, with molecular profiling services revenue reaching $766.7 million, up 120% compared to 2024. The company achieved positive GAAP net income of $82 million, adjusted EBITDA of $106 million, and free cash flow of $39.7 million in Q4 2025, ending the year with over $800 million in cash on hand.
- The company's molecular data set now exceeds 1 million profiled cases, and it completed just under 200,000 individual cases in 2025.
- Caris Life Sciences provided 2026 full-year guidance, expecting total revenue for existing solutions to be in the range of $1.0 billion-$1.02 billion, representing 23%-26% growth over 2025. Molecular profiling is projected to grow 21%-22%, and pharma and research revenue is expected to be $75 million-$85 million.
- The launch of Caris Detect, a whole genome sequencing-based MCED blood test, is anticipated in Q2 2026.
2 days ago
Caris Life Sciences Reports Q4 and Full Year 2025 Results, Provides 2026 Outlook
CAI
Earnings
Guidance Update
Revenue Acceleration/Inflection
- Caris Life Sciences reported Q4 2025 total revenue of $292.9 million, a 125% increase over the prior year period, and full year 2025 total revenue of $812.0 million, a 97% increase over the prior year.
- For Q4 2025, the company achieved net income of $82.0 million and Adjusted EBITDA of $106.1 million. For the full year 2025, it reported a net loss of $68.1 million but positive Adjusted EBITDA of $137.7 million.
- The company generated positive net cash provided by operating activities of $44.8 million in Q4 2025 and $83.2 million for the full year 2025.
- Caris Life Sciences expects full year 2026 revenue to be in the range of $1.0 billion to $1.02 billion, representing 23% to 26% growth compared to full year 2025.
- The 2026 outlook also includes expected clinical therapy selection volume growth of approximately 20% and the anticipation of remaining positive on Free Cash Flow and Adjusted EBITDA.
2 days ago
Caris Life Sciences Reports Q4 and Full Year 2025 Financial Results and Provides 2026 Outlook
CAI
Earnings
Guidance Update
Revenue Acceleration/Inflection
- For the full year ended December 31, 2025, Caris Life Sciences reported total revenue of $812.0 million, a 97% increase over the prior year, and a net loss of $68.1 million.
- In the fourth quarter of 2025, the company achieved total revenue of $292.9 million, a 125% increase over the corresponding prior year period, and a net income of $82.0 million.
- The company reported positive Adjusted EBITDA of $137.7 million and positive free cash flow of $66.9 million for the full year 2025.
- Caris Life Sciences completed approximately 199,300 clinical therapy selection cases in full year 2025, an increase of approximately 22% over the prior year.
- For full year 2026, Caris Life Sciences expects revenue to be in the range of $1.0 billion to $1.02 billion, representing 23% to 26% growth compared to full year 2025, and anticipates remaining positive on Free Cash Flow and Adjusted EBITDA.
2 days ago
Caris Life Sciences Launches New AI Insights Signature for Breast Cancer
CAI
Product Launch
New Projects/Investments
- Caris Life Sciences (NASDAQ: CAI) announced a new breast cancer signature for capecitabine, included in the Caris Molecular Tumor Board Report.
- This AI-powered signature uses over 2,000 expression and copy number features to predict response to capecitabine for first-line chemotherapy in HER2-negative breast cancer patients.
- The Caris Molecular Tumor Board Report, which includes these AI Insights, is available upon request when ordering MI Cancer Seek.
- MI Cancer Seek received FDA approval in November 2024 as the first and only simultaneous Whole Exome Sequencing (WES) and Whole Transcriptome Sequencing (WTS)-based assay with FDA-approved companion diagnostic indications for molecular profiling of solid tumors.
5 days ago
CAI Reports Strong 2025 Financial Performance and Strategic Growth
CAI
Earnings
New Projects/Investments
Revenue Acceleration/Inflection
- CAI closed 2025 with nearly $1.4 billion in revenue, sustaining a five-year compound annual growth rate of nearly 10%.
- The company's Public Sector portfolio experienced over 14% growth, and CAI filled 14% more staffing positions year-over-year. The firm also launched a cyber insurance assessment and advanced AI-powered solutions like its Service Desk.
- CAI contributed over $8 million globally to philanthropic initiatives and received a Gold Globee® Award for Achievement in the Business Philanthropist Company of the Year, among 13 total awards and certifications.
Feb 17, 2026, 2:04 PM
Caris Life Sciences Reports Strong 2025 Financials and Outlines 2026 Growth Initiatives
CAI
Earnings
Product Launch
New Projects/Investments
- Caris Life Sciences ended 2025 with over $800 million in cash and a strong P&L generating significant cash flows and profitability, driven by ASP pricing.
- The company reported $281 million in revenue for 2025, which included $135 million in true-ups (with $102 million related to 2025 cases). The Q4 tissue base ASP was $3,800, and blood ASP stepped up to $2,500.
- In 2025, Caris completed 199,300 individual genomic profiles, representing a 22% case volume increase for the year, and surpassed 1 million individual genomic profiles in its data set.
- Key product pipeline developments include the imminent launch of Caris ChromaSEQ (whole genome for hematological malignancies) pending MolDX review, the MyClarity AI-driven assay for breast cancer recurrence, and a new whole genome-based tissue-informed MRD assay.
- Caris closed a Caris Discovery project with Genentech with a $20 million upfront milestone payment and a total contract value over $1 billion, which is expected to contribute to 2026 revenue. The company plans to expand its commercial organization and pharma team by 20-25% headcount in 2026 to drive growth.
Jan 12, 2026, 9:30 PM
Caris Life Sciences Reports Strong Q4 2025 Revenue Growth and Pipeline Advancements
CAI
Revenue Acceleration/Inflection
Product Launch
New Projects/Investments
- Caris Life Sciences reported $281 million in Q4 2025 revenues, reflecting 116% year-over-year growth, and ended 2025 with over $800 million in cash.
- The company processed 199,300 genomic profiles in 2025, a 22% year-over-year increase, bringing its total data set to over 1 million individual genomic profiles.
- Key pipeline updates include expected AchieveOne study results by the end of Q1 2026 for its Multi-Cancer Early Detection (MSED) test, which will launch commercially with EverlyWell at a $3,500 price point.
- For 2026, Caris plans significant investments, including a 20%-25% increase in commercial sales headcount and a substantial expansion of its pharma team to drive further growth.
- A Caris Discovery project with Genentech was finalized in late Q4 2025, featuring a $20 million upfront milestone payment and a total contract value exceeding $1 billion.
Jan 12, 2026, 9:30 PM
Quarterly earnings call transcripts for Caris Life Sciences.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more